June 2026 Research Brief
Active sponsors
Trials
Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE Trial
Intelligent Screening and Precision Diagnosis of Prostate Cancer Based on Multimodal Data
Nudging Preventive Screening Via Message Framing and Bundling
RISK-ADAPT Protocol in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
This Study Evaluates the Diagnostic Performance and Safety of 68Ga-NYM032 PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer.
Water Vapor Ablation for Grade Group 3 Prostate Cancer
Spinal Versus General Anesthesia in Open Simple Prostatectomy
PSMA PET/CT-Guided SBRT Plus Darolutamide in mHSPC
WATER IV PCa (AS Sub-study)
Risk Factors, Incidence, and Progression of Lymphedema Among Men With Prostate Cancer. The AWARE Cohort
Showing trials with activity in the past 30 days. See the full Prostate Cancer research landscape →
Recently completed · awaiting results
Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC
Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer
Evaluation of the Medical Service by Socio-aesthetics in Oncology
Effect of Education to be Provided to Patients to Undergo TURP With Mobile Application on Patient Outcomes
Condition guide
Prostate Cancer — the full picture
Research landscape, trial types, and what eligibility typically looks like — written for patients but useful for everyone.
Monthly digest
Get this brief every month
We’ll email you the Prostate Cancerbrief as soon as it’s published — no login required.
Coming soon